Biocon, Mylan launch cancer drug in Canada

Fulphila, co-developed by Biocon Biologics and Mylan, was the first
biosimilar pegfilgrastim to be approved in the US and was launched in
July 2018.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-mylan-launch-cancer-drug-in-canada/articleshow/75434205.cms

Comments

Popular posts from this blog

The Scroll and the Revolution: The Dilemmas of Writing about the Jews of Cuba

The Right Tool for the Job: Foreign Policy Effectiveness and Nuclear Proliferation

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply